Spark Therapeutics, Inc. (NASDAQ:ONCE) Files An 8-K Results of Operations and Financial Condition

Spark Therapeutics, Inc. (NASDAQ:ONCE) Files An 8-K Results of Operations and Financial Condition
Item 2.02.

Story continues below

Results of Operations and Financial Condition

On January7, 2019, Spark Therapeutics, Inc. (the “Company”) will be providing financial information, including information about the Company’s estimated cash balance and the number of vials the Company has shipped of its product, LUXURNA® (voretigene neparvovec-rzyl) as of December 31, 2018, in the Company’s presentation at the 2019 J.P. Morgan Healthcare Conference (the “JPMorgan Conference”) and meetings with investors. As of December31, 2018, the Company’s approximate cash and cash equivalents, restricted cash and marketable securities was $601 million and the Company had shipped 75 vials of LUXTURNA.

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02.

Regulation FD Disclosure

As referenced above, the Company will be giving a presentation at the JPMorgan Conference on January7, 2019. A copy of the presentation, including a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation, is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02.

Financial Statements and Exhibits

(d) Exhibits

Exhibit99.1

Spark Therapeutics, Inc. Presentation for the 2019 J.P. Morgan Healthcare Conference dated January 7, 2019

Spark Therapeutics, Inc. Exhibit
EX-99.1 2 jpm2019posteddeck.htm EXHIBIT 99.1 jpm2019posteddeck Corporate Overview January 2019 1 Investor communication only: Not for use in promotion   Forward-looking statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995,…
To view the full exhibit click here

About Spark Therapeutics, Inc. (NASDAQ:ONCE)

Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington’s disease, a hereditary genetic disorder.

An ad to help with our costs